Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service dialysis access cases in Nevada: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (245 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 23 | 3,362 | 42% |
| 2020 | 22 | 3,458 | 45% |
| 2021 | 18 | 2,782 | 48% |
| 2022 | 18 | 2,387 | 51% |
| 2023 | 21 | 2,212 | 54% |
| 2024 | 20 | 2,124 | 56% |
| 2025 from claims | – | 2,065 1,895–2,184 | 57% |
| 2026 forecast | – | 2,097 1,845–2,419 | 57% |
| 2027 forecast | – | 2,120 1,812–2,526 | 58% |
| 2028 forecast | – | 2,143 1,788–2,624 | 58% |
| 2029 forecast | – | 2,165 1,769–2,716 | 59% |
| 2030 forecast | – | 2,188 1,753–2,804 | 60% |
AV fistula and graft creation, access circuit angioplasty and stenting. Professional codes (what the surgeon bills): CPT 36821, 36830, 36902, 36903, 36905, 36906, 36818, 36819.
Since 2021 dialysis (ESRD) patients may join Medicare Advantage, and they have moved to it far faster than the county average, so fee-for-service decline here overstates the real one even after adjustment.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 82% of the cases CMS names in Nevada; 10 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 1% inpatient hospital, 3% hospital outpatient, 95% surgery center, 1% office. The share outside the hospital has moved +8 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center |
|---|---|---|---|
| 2026 · ~2,100 | ~15 | ~52 | ~2,000 |
| 2027 · ~2,100 | ~14 | ~46 | ~2,100 |
| 2028 · ~2,100 | ~13 | ~43 | ~2,100 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 97% (95% in 2025), hospital outpatient about 2% (3% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 204 | 20,282−7.2%/yr | −7.2%/yr | 6.3 | 68% | 20,800 in 2030+0.5%/yr |
| Arizona | 33 | 3,680−7.6%/yr | −7.6%/yr | 5.2 | 88% | 4,140 in 2030+2%/yr |
| Washington | 30 | 2,051−12%/yr | −12%/yr | 2.8 | 19% | 1,780 in 2030−2.4%/yr |
| Colorado | 23 | 1,386−15%/yr | −15%/yr | 3.0 | 39% | 1,300 in 2030−1.1%/yr |
| Oregon | 16 | 1,041−9.9%/yr | −9.9%/yr | 2.6 | 56% | 1,090 in 2030+0.7%/yr |
| New Mexico | 7 | 658−16%/yr | −16%/yr | 3.0 | 83% | 1,090 in 2030+8.7%/yr |
| Utah | 9 | 647−6.1%/yr | −6.1%/yr | 3.1 | 40% | 580 in 2030−1.7%/yr |
| Hawaii | 8 | 567−14%/yr | −14%/yr | 4.6 | 62% | 560 in 2030−0.1%/yr |
| Idaho | 7 | 518−3.1%/yr | −3.1%/yr | 2.6 | 0% | 510 in 2030−0.2%/yr |
| Alaska | 8 | 491+1.8%/yr | +1.8%/yr | 4.1 | 49% | 400 in 2030−3.2%/yr |
| Montana | 1 | 182−11%/yr | −11%/yr | 1.0 | 0% | 260 in 2030+6.4%/yr |
| Wyoming | 1 | 101−4.5%/yr | −4.5%/yr | 0.9 | 0% | 100 in 2030+0.4%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Superficial venous ablation | 19 | 2,060−8.7%/yr | −8.7%/yr | 6.81.2× | 99% | 2,270 in 2030+1.7%/yr |
| Peripheral arterial intervention | 9 | 1,215−6.2%/yr | −6.2%/yr | 4.00.8× | 73% | 1,790 in 2030+6.7%/yr |
| Thrombectomy, IVC filters & venous stents | 3 | 412−4.7%/yr | −4.7%/yr | 1.41.2× | 0% | 540 in 2030+4.7%/yr |
| Carotid revascularization | 11 | 315−0.4%/yr | −0.4%/yr | 1.11.3× | 0% | 610 in 2030+11%/yr |
| Aortic endografts (EVAR/TEVAR) | 0 | 117−8%/yr | −8%/yr | 0.41.3× | 0% | 100 in 2030−2.4%/yr |
Dialysis access in every state, and its device makers · Every procedure market in Nevada · Every state · Compare with California
BD leads with 52% of company spending on these surgeons in 2025, +51 pts on 2024.
In 2025, 4 companies reported engagement with Nevada’s surgeons worth $1,010 in consulting, speaking, meals and travel tied to these products, about $51 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 1 clearance or approval in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.